Regenxbio (RGNX) Other financing activities (2015 - 2025)
Regenxbio (RGNX) posted quarterly Other financing activities of $90000.0 for Q4 2025, up 136.84% year-over-year from $38000.0 in Q4 2024, and up 15.38% quarter-over-quarter from $78000.0 in Q2 2025.
Regenxbio (RGNX) Other financing activities (2015 - 2025) Analysis & Trends
Regenxbio's Other financing activities history runs 11 years deep, the most recent figure standing at $90000.0 for Q4 2025.
- In Q4 2025, Other financing activities rose 136.84% year-over-year to $90000.0; the TTM figure through Dec 2025 stood at $318000.0 (down 78.97% YoY), while the FY2025 annual figure was $318000.0, down 78.97% from the prior year.
- Other financing activities for Q4 2025 stood at $90000.0, up from $78000.0 in the prior quarter.
- The five-year high for Other financing activities was $2.5 million in Q4 2021, with the low at $38000.0 in Q4 2024.
- The 5-year median for Other financing activities is $411000.0 (2024), against an average of $632941.2.
- The sharpest annual moves came in 2022 and 2023: Other financing activities slumped 98.3% in 2022, then surged 1095.35% in 2023.
- Regenxbio's Other financing activities stood at $2.5 million in 2021, then plunged by 98.3% to $43000.0 in 2022, then soared by 1095.35% to $514000.0 in 2023, then sank by 92.61% to $38000.0 in 2024, then surged by 136.84% to $90000.0 in 2025.
- Business Quant data shows RGNX's Other financing activities at $90000.0 in Q4 2025, $78000.0 in Q2 2025, and $150000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 90,000.00 |
| Dec 31, 2025 | 90,000.00 |
| Jun 30, 2025 | 78,000.00 |
| Jun 30, 2025 | 78,000.00 |
| Mar 31, 2025 | 150,000.00 |
| Mar 31, 2025 | 150,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Sep 30, 2024 | 398,000.00 |
| Sep 30, 2024 | 398,000.00 |
| Jun 30, 2024 | 665,000.00 |
| Jun 30, 2024 | 665,000.00 |
| Mar 31, 2024 | 411,000.00 |
| Mar 31, 2024 | 411,000.00 |
| Dec 31, 2023 | 514,000.00 |
| Dec 31, 2023 | 514,000.00 |
| Sep 30, 2023 | 729,000.00 |
| Sep 30, 2023 | 729,000.00 |
| Jun 30, 2023 | 583,000.00 |
| Jun 30, 2023 | 583,000.00 |